Clinical trial conducted by Barcelona's Vall d'Hebron Hospital shows that a combination of two new antibodies reduces tumor reduction in colorectal metastatic cancers by 67%.
Colorectal metastatic cancers that no longer respond to conventional treatment showed a reduction in tumor growth.
Josep Tabernero, head of Medical Oncology at Vall d'Hebron Hospital and director of the Vall d'Hebron Oncology Institute, said, "This is important progress because we have showed this improvement for the first time in a clinical phase, although it is just one more step, it does not cure cancer, it only gives us more control time".
"Sym004", a mixture of two antibodies that act against the epidermal growth factor receptor protein, is effective in patients with advanced colorectal cancer who had become resistant to previous treatments with therapies inhibiting this protein.
This new drug opens the possibility for a treatment with better results in these advanced colon cancer cases. This is the second most common cancer type in the world with around 1.36 million new cases and 694,000 deaths every year.